NCL, CPTAC-936 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

10 20 30 40 50
MVKLAKAGKN QGDPKKMAPP PKEVEEDSED EEMSEDEEDD SSGEEVVIPQ
60 70 80 90 100
KKGKKAAATS AKKVVVSPTK KVAVATPAKK AAVTPGKKAA ATPAKKTVTP
110 120 130 140 150
AKAVTTPGKK GATPGKALVA TPGKKGAAIP AKGAKNGKNA KKEDSDEEED
160 170 180 190 200
DDSEEDEEDD EDEDEDEDEI EPAAMKAAAA APASEDEDDE DDEDDEDDDD
210 220 230 240 250
DEEDDSEEEA METTPAKGKK AAKVVPVKAK NVAEDEDEEE DDEDEDDDDD
260 270 280 290 300
EDDEDDDDED DEEEEEEEEE EPVKEAPGKR KKEMAKQKAA PEAKKQKVEG
310 320 330 340 350
TEPTTAFNLF VGNLNFNKSA PELKTGISDV FAKNDLAVVD VRIGMTRKFG
360 370 380 390 400
YVDFESAEDL EKALELTGLK VFGNEIKLEK PKGKDSKKER DARTLLAKNL
410 420 430 440 450
PYKVTQDELK EVFEDAAEIR LVSKDGKSKG IAYIEFKTEA DAEKTFEEKQ
460 470 480 490 500
GTEIDGRSIS LYYTGEKGQN QDYRGGKNST WSGESKTLVL SNLSYSATEE
510 520 530 540 550
TLQEVFEKAT FIKVPQNQNG KSKGYAFIEF ASFEDAKEAL NSCNKREIEG
560 570 580 590 600
RAIRLELQGP RGSPNARSQP SKTLFVKGLS EDTTEETLKE SFDGSVRARI
610 620 630 640 650
VTDRETGSSK GFGFVDFNSE EDAKAAKEAM EDGEIDGNKV TLDWAKPKGE
660 670 680 690 700
GGFGGRGGGR GGFGGRGGGR GGRGGFGGRG RGGFGGRGGF RGGRGGGGDH
710
KPQGKKTKFE

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader


Assay Details for CPTAC-936 Collapse assay details

Data source: Panorama

Official Gene Symbol

NCL

Peptide Modified Sequence

GFGFVDFNS[+80.0]EEDAK

Modification Type

Phospho (ST)

Protein - Site of Modification

619

Peptide - Site of Modification

9

Peptide Start

611

Peptide End

624

CPTAC ID

CPTAC-936

Peptide Molecular Mass

1,640.6396

Species

Homo sapiens (Human)

Assay Type

Enrichment MRM

Enrichment Method

IMAC

Matrix

cell lysate

Submitting Laboratory

Fred Hutchinson Cancer Research Center

Submitting Lab PI

Amanda Paulovich


Publication

View Details (opens in a new window)

Kennedy JJ, Yan P, Zhao L, Ivey RG, Voytovich U, Moore HD, Lin C, Pogosova-Agadjanyan EL, Stirewalt DL, Reding KW, Whiteaker JR, Paulovich AG. Immobilized metal affinity chromatography coupled to multiple reaction monitoring enables reproducible quantification of phospho-signaling. Molecular and Cellular Proteomics. mcp.O115.054940


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

QTrap 5500 (Sciex)

Internal Standard

Peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C and 15N at C-terminus K

LC

nanoLC-2D (Eksigent)

Column Packing

ChromXP C18-CL, 3 µm, 120 Å

Column Dimensions

75 µm x 15cm

Flow Rate

300 nL/min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y9 (1+) | 28.7 | 9.8 | 5.2 | 21.7 | 18.8 | 6 | 36 | 21.2 | 7.9 | 15 | 24 | 15 | | y10-98 (1+) | 39.5 | 8.7 | 7.9 | 29.6 | 20.4 | 8.4 | 49.4 | 22.2 | 11.5 | 15 | 24 | 15 | | y10 (1+) | 38.5 | 7.9 | 6.6 | 37.4 | 17.2 | 6.4 | 53.7 | 18.9 | 9.2 | 15 | 24 | 15 | | sum | 29.7 | 7.8 | 5.8 | 21.2 | 18.4 | 5.7 | 36.5 | 20 | 8.1 | 15 | 24 | 15 |



Additional Resources and Comments